Geron Corp. (GERN) Rating Reiterated by BTIG Research
Geron Corp. (NASDAQ:GERN)‘s stock had its “neutral” rating reissued by analysts at BTIG Research in a research note issued on Tuesday.
Several other brokerages also recently commented on GERN. Zacks Investment Research upgraded shares of Geron Corp. from a “hold” rating to a “strong-buy” rating and set a $3.00 price target for the company in a research report on Friday, August 5th. Piper Jaffray Cos. restated an “overweight” rating and issued a $5.00 price target (down previously from $10.00) on shares of Geron Corp. in a research report on Tuesday, September 13th. Finally, FBR & Co reduced their price target on shares of Geron Corp. from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Tuesday, September 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $5.00.
Geron Corp. (NASDAQ:GERN) opened at 2.25 on Tuesday. The firm has a 50-day moving average of $2.61 and a 200-day moving average of $2.79. Geron Corp. has a one year low of $1.84 and a one year high of $5.30. The firm has a market cap of $358.06 million, a price-to-earnings ratio of 281.25 and a beta of 2.63.
Geron Corp. (NASDAQ:GERN) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.02. The business earned $0.21 million during the quarter, compared to the consensus estimate of $0.38 million. Geron Corp. had a net margin of 3.39% and a return on equity of 0.89%. The firm’s quarterly revenue was down 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.06) EPS. Analysts anticipate that Geron Corp. will post ($0.23) EPS for the current year.
A number of large investors have recently added to or reduced their stakes in GERN. Commonwealth Equity Services Inc increased its stake in Geron Corp. by 0.3% in the second quarter. Commonwealth Equity Services Inc now owns 73,397 shares of the biopharmaceutical company’s stock worth $197,000 after buying an additional 200 shares during the last quarter. IFP Advisors Inc increased its stake in Geron Corp. by 1.9% in the first quarter. IFP Advisors Inc now owns 35,090 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 650 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Geron Corp. by 0.7% in the first quarter. Metropolitan Life Insurance Co. NY now owns 113,715 shares of the biopharmaceutical company’s stock worth $332,000 after buying an additional 839 shares during the last quarter. Rhumbline Advisers increased its stake in Geron Corp. by 0.5% in the second quarter. Rhumbline Advisers now owns 156,877 shares of the biopharmaceutical company’s stock worth $420,000 after buying an additional 840 shares during the last quarter. Finally, Creative Planning raised its position in shares of Geron Corp. by 3.5% in the second quarter. Creative Planning now owns 59,700 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 2,000 shares during the period. Institutional investors own 38.09% of the company’s stock.
Geron Corp. Company Profile
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.
Receive News & Ratings for Geron Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corp. and related companies with MarketBeat.com's FREE daily email newsletter.